Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Drug Development
Sort By
Newest First
1 / 35
Particle Analysis
Advancing Subvisible Particle Characterization with Artificial Intelligence
Daniel Weinbuch, Ph.D.
Coriolis Pharma
PAO-03-25-CL-02
Mar 11, 2025
Oncology
From Coley’s Toxins to mRNA: Reflecting on the History of Cancer Vaccines
David Alvaro, Ph.D.
Pharma's Almanac
PAO-25-30-03
Mar 02, 2025
Personalized
Personalized Medicine and the CDMO: Adapting to a New Era of Healthcare
Ola Tuvesson; Isa Lindgren, Ph.D.
NorthX Biologics
PAO-01-25-CL-09
Feb 14, 2025
Drug Development
Nektar Therapeutics Receives Fast Track Designation for the Treatment of Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
PR-02-25-NI-07
Feb 10, 2025
Drug Development
FDA Accepts Integral Molecular's Membrane Proteome Array™ Qualification Plan, Advancing Approval Platform of Drug Development Tool
Integral Molecular
PR-02-25-NI-04
Feb 08, 2025
Developability
Streamlining Drug Development with Integrated In Silico and Laboratory Developability Assessments
Andrea Arsiccio, Ph.D.,; Eva Keilhauer, Ph.D.; Kristian Le Vay, Ph.D.
Coriolis Pharma
PAO-01-25-CL-12
Jan 27, 2025
Drug Development
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
REGENXBIO
PR-01-25-NI-12
Jan 14, 2025
Clinical Trials
New SELECT trial analysis with semaglutide 2.4 mg showed a reduction in hospital admissions with heart disease and overweight
Novo Nordisk
PR-10-24-NI-74
Nov 05, 2024
Clinical Trials
TREMFYA is the first and only IL-23 inhibitor to demonstrate robust results with regimen in both induction and maintenance
Johnson & Johnson
PR-10-24-NI-64
Oct 28, 2024
FDA
U.S. Food and Drug Administration
U.S. Food & Drug Administration
PR-10-24-NI-44
Oct 14, 2024
FDA
SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia
Systimmune, Inc.
PR-10-24-NI-42
Oct 14, 2024
Financing
AMD Drugs Market to Hit USD 17.37 Billion by 2029 with 10.7% CAGR | MarketsandMarkets™
MarketsandMarkets™
PR-09-24-NI-22
Sep 27, 2024
Bispecifics
Revolutionizing Autoimmune Disease Management with Soluble Bispecific Receptors
Gardiner Smith; Reiner Gentz, Ph.D.
Fab Biopharma
PR-09-24-NI-19
Sep 27, 2024
Female-Centric
Transforming Drug Development through a Female Perspective
Chia Chia Sun; William Freimuth, Ph.D., M.D.
Fab Biopharma
PAO-09-24-CL-03
Sep 10, 2024
Developability
Mitigating Early Development Risks with Samsung Biologics DEVELOPICK™ Platform
Heonchang Lim
Samsung Biologics
PAO-09-24-CL-04
Sep 04, 2024
Drug Delivery
Nanocarriers to Overcome the Blood–Brain Barrier (BBB)
Serene Lee
Nice Insight
PAO-09-24-NI-01
Aug 30, 2024
Changing Roles
How are Advancements in Technology Reshaping the Roles and Capabilities of CDMOs and CROs in the Drug Development Life Cycle?
Pharma's Almanac
PAO-08-24-RT-01
Aug 07, 2024
Nice Insight API Report
Small Molecule API Discovery and Development Trends
April Stanley, MS MBA
Nice Insight
PAO-03-24-NI-01
Mar 21, 2024
Digital Pathology
Advancing Disease Research and Drug Development on an Enterprise Pathology Software Platform
Nathan Buchbinder
Proscia
PAO-01-24-CL-2
Feb 29, 2024
CDMO - Small Biotech
Cis-Targeted Immunotherapies Need Large CDMO Expertise But Also Flexibility
Julie Trulson, Ph.D.
PAO-02-24-CL-07
Feb 15, 2024
1 / 35
